Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | Pyruvate dehydrogenase (lipoamide) kinase | 0.3691 | 0.3254 | 0.5 |
Trypanosoma cruzi | developmentally regulated phosphoprotein, putative | 0.3691 | 0.3254 | 0.5 |
Echinococcus granulosus | Pyruvate dehydrogenase lipoamide kinase | 0.3691 | 0.3254 | 0.5 |
Toxoplasma gondii | ATPase/histidine kinase/DNA gyrase B/HSP90 domain-containing protein | 0.1496 | 0 | 0.5 |
Schistosoma mansoni | pyruvate dehydrogenase | 0.3691 | 0.3254 | 1 |
Mycobacterium ulcerans | carbon monoxyde dehydrogenase large chain CoxL | 0.3887 | 0.3543 | 0.5951 |
Mycobacterium ulcerans | carbon monoxide dehydrogenase | 0.5461 | 0.5876 | 1 |
Trypanosoma brucei | developmentally regulated phosphoprotein | 0.3691 | 0.3254 | 0.5 |
Leishmania major | developmentally regulated phosphoprotein-like protein | 0.3691 | 0.3254 | 0.5 |
Mycobacterium tuberculosis | Probable carbon monoxyde dehydrogenase (medium chain) | 0.2783 | 0.1908 | 0.5229 |
Mycobacterium tuberculosis | Probable carbon monoxyde dehydrogenase (large chain) | 0.3887 | 0.3543 | 1 |
Trichomonas vaginalis | xanthine dehydrogenase, putative | 0.8244 | 1 | 0.5 |
Brugia malayi | kinase, mitochondrial precursor | 0.3691 | 0.3254 | 0.5 |
Mycobacterium ulcerans | aerobic-type carbon monoxide dehydrogenase subunit CoxM_2 | 0.2783 | 0.1908 | 0.3111 |
Loa Loa (eye worm) | hypothetical protein | 0.3691 | 0.3254 | 0.5 |
Mycobacterium ulcerans | carbon monoxyde dehydrogenase medium chain CoxM | 0.2783 | 0.1908 | 0.3111 |
Mycobacterium ulcerans | aerobic-type carbon monoxide dehydrogenase subunit CoxL_2 | 0.3887 | 0.3543 | 0.5951 |
Trichomonas vaginalis | aldehyde oxidase, putative | 0.8244 | 1 | 0.5 |
Mycobacterium ulcerans | carbon monoxyde dehydrogenase large chain CoxL | 0.2444 | 0.1405 | 0.2238 |
Echinococcus multilocularis | Pyruvate dehydrogenase (lipoamide) kinase | 0.3691 | 0.3254 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
GI50 (functional) | -5.449 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HL-60(TB) Leukemia cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -5.439 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the ACHN Renal cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -5.338 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-5 Melanoma cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -5.32 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the MALME-3M Melanoma cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -5.105 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the NCI-H23 Non-Small Cell Lung cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -5 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SN12C Renal cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -5 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the UO-31 Renal cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4.54 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HOP-92 Non-Small Cell Lung cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SF-539 Central Nervous System cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.